跳至主要内容
临床试验/CTRI/2020/09/027603
CTRI/2020/09/027603尚未招募4 期

An Open Label, Prospective, Non-comparative,Multicentric,Single Arm, Active Post Marketing Surveillance Study to Evaluate the Safety, Tolerability and Efficacy of FDC of Pregabalin 75 mgand Nortriptyline 10 mg Tablets in Adult Patients for the treatment of Neuropathic Pain.

Aeon Formulations Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Adults male or female patients aged 18 to 65 years (both inclusive), diagnosed with neuropathic pain and who require treatment with FDC of Pregabalin 75 mg and Nortriptyline 10 mg Tablets as part of their routine treatment regimen

排除标准

  • 1. Patients with known hypersensitivity to Pregabalin / Nortriptyline.
  • 2. Females of childbearing age not using effective contraception/nursing & pregnant females.
  • 3. Patients predisposed to Thrombocytopenia / liver dysfunction / renal impairment. 4. Patients with known history of myocardial infarction (MI) / cardiac arrhythmia.

研究者

发起方
Aeon Formulations Pvt Ltd

相似试验